Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
May 22, 2023
May 22, 2023
MedinCell announces the successful pricing of its Global Offering and raises €25 million
May 12, 2023
May 12, 2023
MedinCell launches a Global Offering for approximately 25 million euros
May 11, 2023
May 11, 2023
MedinCell: mdc-TJK’s (Teva’s codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
